Shire Premacure Buy Moves HGT Into Neonatology
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma announced its second acquisition this year, adding another mid-stage asset to its rare disease unit, this time a protein replacement therapy for an eye disorder that affects premature infants.